Antibody array data showing activation of kinases in human red blood cells infected with the malaria parasite.
New research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself, could offer effective treatment for a range of infectious diseases, including COVID-19.
The study, conducted by an international team and led by RMIT University’s Professor Christian Doerig, outlines a strategy that could save years of drug discovery research and millions of dollars in drug development by repurposing existing treatments designed for other diseases such as cancer.
The approach shows so much promise it has received government funding for its potential application in the fight against COVID-19.
The study, published in Nature Communications, demonstrated that the parasites that cause malaria are heavily dependent on enzymes in red blood cells where the parasites hide and proliferate.
It also revealed that drugs developed for cancer, and which inactivate these human enzymes, known as protein kinases, are highly effective in killing the parasite and represent an alternative to drugs that target the parasite itself.
Lead author, RMIT’s Dr Jack Adderley, said the analysis revealed which of the host cell enzymes were activated during infection, revealing novel points of reliance of the parasite on its human host.
“This approach has the potential to considerably reduce the cost and accelerate the deployment of new and urgently needed antimalarials,” he said
“These host enzymes are in many instances the same as those activated in cancer cells, so we can now jump on the back of existing cancer drug discovery and look to repurpose a drug that is already available or close to completion of the drug development process.”
As well as enabling the repurposing of drugs, the approach is likely to reduce the emergence of drug resistance, as the pathogen cannot escape by simply mutating the target of the drug, as is the case for most currently available antimalarials.
Doerig, Associate Dean for the Biomedical Sciences Cluster at RMIT and senior author of the paper, said the findings were exciting, as drug resistance is one of the biggest challenges in modern healthcare, not only in the case of malaria, but with most infectious agents, including a large number of highly pathogenic bacterial species.
“We are at risk of returning to the pre-antibiotic era if we don’t solve this resistance problem, which constitutes a clear and present danger for global public health. We need innovative ways to address this issue,” he said.
“By targeting the host and not the pathogen itself, we remove the possibility for the pathogen to rapidly become resistant by mutating the target of the drug, as the target is made by the human host and not by the pathogen.”
Doerig’s team will now collaborate with the Peter Doherty Institute for Infection and Immunity (Doherty Institute) to investigate potential COVID-19 treatments using this approach, supported by funding from the Victorian Medical Research Acceleration Fund in partnership with the Bio Capital Impact Fund (BCIF).
Co-investigator on the grant, Royal Melbourne Hospital’s Dr Julian Druce, of the Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Doherty Institute, was part of the team that were first to grow and share the virus that causes COVID-19, and said the research was an important contribution to efforts to defeat the pandemic.
Royal Melbourne Hospital’s Professor Peter Revill, Senior Medical Scientist at the Doherty Institute and a leader on Hepatitis B research, said the approach developed by the RMIT team was truly exciting.
“This has proven successful for other human pathogens including malaria and Hepatitis C virus, and there are now very real prospects to use it to discover novel drug targets for Hepatitis B and COVID-19,” he said.
The paper is the outcome of an RMIT-led international collaboration with researchers from Monash University in Melbourne, Dr Danny Wilson (University of Adelaide’s Malaria Biology Laboratory Head, The Hospital Research Foundation Fellow and Burnet Institute), Dr Jean-Philippe Semblat (from French Government agency Inserm, Paris) and Prof Oliver Billker (Umeå University, Sweden and Wellcome Sanger Institute, UK).
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- The fatal chink in malaria parasite's armoron March 4, 2021 at 4:58 am
Researchers from The Australian National University (ANU) have exposed a fatal flaw in the deadly parasite that causes malaria—one of the world's biggest killers.
- 19 Unsung Scientists Who Didn’t Get Enough Crediton March 4, 2021 at 4:00 am
From under-appreciated geologists to the first woman to fly in space, here are just a few scientists who didn't get enough credit for their work.
- This discovery of 29 ‘new’ mosquito genes could open door to curbing malaria spread in Indiaon March 1, 2021 at 6:00 pm
Scientists in India and the US discovered 29 genes in malaria-causing mosquitoes that make the mosquito resistant to insecticides.
- Intestinal worms throw open the door to dangerous viruseson February 26, 2021 at 2:06 pm
Some regions where these worms are endemic also have unusually high rates of infectious diseases, such as malaria. Michael Diamond at the ... pathogens than when infected with just one. The team ...
- Kala-azar: Over 15 people in Mandera infected by world’s second-largest parasitic killer after malariaon February 25, 2021 at 3:45 am
Over 15 people in Mandera have been infected by Kala-azar, the world’s second-largest parasitic killer after malaria. The disease is common in America & Asia.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Targeting host enzymes to fight disease
- A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastomaon March 3, 2021 at 5:07 am
We and others have shown that increased MYCN protein stability is acquired by neuroblastoma cells, even in the presence of MYCN amplification, by multiple feed-forward expression loops involving MYCN ...
- New drug shows potential as prophylactic for Alzheimer’s diseaseon March 2, 2021 at 6:20 pm
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
- Researchers find effective combination of therapies for managing mitochondrial diseaseon March 2, 2021 at 9:47 am
Researchers from the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia (CHOP) have demonstrated how one combination of therapies may be beneficial for patients with ...
- Establishing Links Between Certain Inflammatory Diseaseson February 25, 2021 at 5:56 am
How two companies came together to target a source of type 2 inflammation that may drive asthma, eczema and chronic rhinosinusitis with nasal polyposis.
- NOX5: a novel target for sensitising melanoma to therapieson February 19, 2021 at 9:59 am
Vito Quaranta discusses how cancers adopting novel mechanisms of energy production could be sensitised to therapies with a focus on melanoma.